Literature DB >> 15756674

Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.

Johan W Molling1, Wendy Kölgen, Hans J J van der Vliet, Martijn F Boomsma, Hinke Kruizenga, Carolien H Smorenburg, Barbara G Molenkamp, Johannes A Langendijk, C René Leemans, B Mary E von Blomberg, Rik J Scheper, Alfons J M van den Eertwegh.   

Abstract

Natural killer T (NKT) cells are CD1d-restricted lymphoid cells and are characterized by an invariant T-cell receptor, which in humans consists of a Valpha24 chain paired with a Vbeta11 chain. These cells are known for their rapid production of large amounts of cytokines (e.g., IFN-gamma and IL-4), thereby modulating other cells of the immune system such as T cells, NK cells and dendritic cells. NKT cells have been reported to play important regulatory roles in many immune responses, including antitumor immune responses. Here, we demonstrate an age-dependent decrease in circulating Valpha24(+)Vbeta11(+) NKT cell numbers in both healthy controls and cancer patients and demonstrate that in both groups females have higher NKT cell levels compared to males. In a large group of 120 cancer patients, we show that circulating Valpha24(+)Vbeta11(+) NKT cell numbers are about 50% lower than in age- and gender-matched healthy controls and that this decrease is independent of tumor type or tumor load. This decrease was not restored upon tumor removal by means of surgery or radiotherapy. Even though the percentage of NKT cells that secrete IFN-gamma, as detected by ELISPOT, is normal in cancer patients, the absolute number of circulating IFN-gamma-secreting NKT cells is reduced. Together, our results suggest that the reduced circulating Valpha24(+)Vbeta11(+) NKT cell numbers in cancer patients are not affected by tumor load, but might actually reflect a risk factor for tumor development, e.g., by hampering efficient tumor immunosurveillance. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756674     DOI: 10.1002/ijc.20998

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

2.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

3.  Effect of Yiqi Bushen Granule (益气补肾颗粒) on the peripheral natural killer cell and γ δ T-cell in the patients with minimal residual leukemia.

Authors:  Yong-gang Xu; Rou Ma; Xiao-hong Yang; Xu-dong Tang; Shu-zhen Sun
Journal:  Chin J Integr Med       Date:  2010-09-25       Impact factor: 1.978

4.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

5.  Altered peripheral invariant natural killer T cells in atopic dermatitis.

Authors:  Edit Gyimesi; Georgina Nagy; Éva Remenyik; Sándor Sipka; Margit Zeher; Tamás Bíró; Andrea Szegedi
Journal:  J Clin Immunol       Date:  2011-06-21       Impact factor: 8.317

Review 6.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

Review 7.  The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.

Authors:  Antonio Romo de Vivar Chavez; Michael E de Vera; Xiaoyan Liang; Michael T Lotze
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

8.  Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Authors:  Tonya J Webb; Joan G Bieler; Jonathan P Schneck; Mathias Oelke
Journal:  J Immunol Methods       Date:  2009-05-14       Impact factor: 2.303

9.  Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Authors:  Weihua Song; Hans J J van der Vliet; Yu-Tzu Tai; Rao Prabhala; Ruojie Wang; Klaus Podar; Laurence Catley; Masood A Shammas; Kenneth C Anderson; Steven P Balk; Mark A Exley; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.